|本期目录/Table of Contents|

[1]祝晓路,罗广承,王新君,等.复发性前列腺增生患者住院主要原因分析[J].慢性病学杂志,2019,20(01):32-35.
　ZHU Xiao-lu,LUO Guang-cheng,WANG Xin-jun,et al.Analysis of the main causes of admission in patients with recurrent prostatic hyperplasia[J].,2019,20(01):32-35.
点击复制

复发性前列腺增生患者住院主要原因分析(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年01期
页码:
32-35
栏目:
论　著
出版日期:
2019-01-30

文章信息/Info

Title:
Analysis of the main causes of admission in patients with recurrent prostatic hyperplasia
作者:
祝晓路;  罗广承;  王新君;  白培明
厦门大学附属中山医院泌尿外科，福建厦门361004
Author(s):
ZHU Xiao-lu;  LUO Guang-cheng;  WANG Xin-jun;  BAI Pei-min
Department of Urology, Zhongshan Hospital, Xiamen University, Fujian 361004, China Corresponding author: LUO Guang-cheng, E-mail: lgch@xmu.edu.cn
关键词:
良性前列腺增生; 复发; 血尿
Keywords:
Benign prostatic hyperplasia;  Palindromia;  Hematuria
分类号:
R699.8
DOI:
-
摘要:
厦门大学附属中山医院泌尿外科，福建厦门361004
Abstract:
Objective To analyze the main causes of admission in patients with recurrent prostatic hyperplasia and discuss its prevention and cure methods. Methods The clinical data of 1 602 cases of benign prostatic hyperplasia in Zhongshan Hospital, Xiamen University from December 2007 to December 2017 were reviewed retrospectively. There were 74 patients with recurrent prostatic hyperplasia （recurrent group） , and the other 1 454 cases were primary group. The main causes of admission in different groups were compared. Results The main cause of readmission in recurrent group was severe hematuria, accounting for 47.30% （35 cases） , which was higher than that in the recurrent group initial admission （χ2=40.66, P<0.01） and the primary group （χ2=143.87, P<0.01） . The primary group was admitted to hospital mainly because of dysuria, accounting for 57.08% （830 cases） , and the main cause of initial admission in recurrent patients was also dysuria, accounting for 56.76% （42 cases） , and there was no significant difference between the two groups （χ2=0.32, P=0.96） . Conclusions Severe hematuria was the main cause of readmission of recurrent prostatic hyperplasia.

参考文献/References:

[1] 俞建军,徐月敏.前列腺增生术后复发的相关因素探讨[J].临床泌 尿外科杂志,2004,19(10):600-601.
[2] 李迎旭,祖雄斌.复发性前列腺增生的诊治(附17 例报告)[J].腹腔 镜外科杂志,2012,17(6):455-457.
[3] Semmens JB, Wisniewski ZS, Bass AJ, et al. Trends in repeat prostatectomy after surgery for benign prostate disease: application of record lineage to health care outcomes [J]. BJU Int, 1999,84(9):972-975.
[4] 毛全宗,荣石,李汉忠,等. 良性前列腺增生经尿道前列腺电切术 后再次电切手术的临床分析[J].中华医学杂志,2004,84(5):372- 374.
[5] Franck- Lissbrant I, Haggestrom S, Damber JE, et al. Testostrrone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats [J]. Endocrinol, 1998,139(2):451-456.
[6] Levine AC, Liu XH, Greenberg PD, et al. Androgens induce the expression of vascular endothelial growth factors in human fetal prostatic fibroblasts [J]. Endocrinol, 1998, 139(11):4672-4678.
[7] 戚景光,曹敬毅,管同郁,等. 良性前列腺增生再次经尿道前列腺 切除术116 例临床分析[J].现代泌尿外科杂志,2007,12(6):387- 389.
[8] Bowden E, Foley S. Hematuria: a late complication of TURP [J]. Prostate Cancer Prostatic Dis, 2001,4(3):178- 179.
[9] 孙庆增,管同郁,戚景光,等. 良性前列腺增生患者经尿道电切术 后再次手术的病理组织学特征分析[J].现代泌尿外科杂志,2010, 15(2):127-130.
[10] Pareek G, Shevchuk M, Anmenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density, a possible mechanism for deceased prostatic bleeding in reared patients [J]. J Urol, 2003,169(1):20-23.
[11] 蓝儒竹,胡志全,庄乾元,等. 非那雄胺对前列腺增生组织中微血 管密度调控的机制探讨[J].华中科技大学学报(医学版),2009,38 (5):703-709.
[12] 崔军,富崴,宋永胜.非那雄胺对大体积前列腺增生组织微血管密 度的影响[J].山西医药杂志,2011,40(11):1075-1077.
[13] Kearney MC, Bingham LB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematurial due to benign prostatic hyperplasia [J]. J Urol, 2002,167(6):2489-2491.
[14] Perimenis P, Gyftopoulos K, Markou S, et al. Effects of finasteride and cyproterone acetate on hematurial associated with benign prostatic hyperplasia: a prospective, randomised, controlled study [J]. Urol, 2002,59(3):373-377.
[15] 姚旭东,唐孝达,夏术阶,等.保列治治疗良性前列腺增生3年疗效 观察[J].临床泌尿外科杂志,2003,18(9):528-530.
[16] 姜玲,朱昀. 长期应用非那雄胺治疗良性前列腺增生临床疗效分 析[J].中华老年医学杂志,2011,30(11):924-925.
[17] 彭涛,庄红雨,许学敏,等. 良性前列腺增生症患者经尿道前列腺 电切术后服用非那雄胺的临床效果及病症影响因素[J]. 中国医 药,2017,12(11):1735-1739.
[18] 刘春晓.传统经尿道前列腺电切术不应再是前列腺增生腔内治疗 的金标准[J].现代泌尿外科杂志,2012,17(3):298-299.
[19] 倪颖,丁雪飞,王启明,等.TURP 术后腺体增生复发反复肉眼血 尿者的再次手术方法探讨[J].海南医学,2014,25(8):1184-1186.
[20] 李传印,郑少波,刘春晓,等. 经尿道逆行腔内剜除双极等离子体 电切治疗复发性前列腺增生[J].临床研究,2014,19(1):26-28.

备注/Memo

备注/Memo:
作者简介：祝晓路，硕士，住院医师，研究方向：泌尿外科 通信作者：罗广承，E-mail：lgch@xmu.edu.cn
更新日期/Last Update: 2019-01-30